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KESAN ANTIKANSER DARIPADA VERNONIA AMYGDALINA TEMPATAN 
DALAM COMBINASI DENGAN STANDARD UBAT KEMOTERAPI, 
TAMOXIFEN ATAS SEL KANSER PAYUDARA, MCF-7 
 
ABSTRAK  
 
Vernonia amygdalina (VA) adalah tumbuhan tempatan yang kerap digunakan di 
Afrika untuk tujuan pemakanan dan terapeutik. Namun demikian, asal geographik, 
tempatan, keadaan cuaca dan masa menuai yang berbeza boleh mempengaruhi aktiviti 
biologikal tumbuhan. Walaupun bidang perubatan sudah menjadi lebih canggih, 
namun kelaziman kanser payu dara masih meningkat di seluruh dunia dan banyak data 
telah menunjukkan dalam semua jenis kanser, ia adalah salah satu daripada kanser 
yang menyumbang kepada kebanyakkan kematian. Selain itu, risiko dan kesan yang 
memudaratkan daripada kemoterapi makin mengimbangi faedahnya. Justeru, kajian 
ini menumpukan atas rawatan kombinasi dengan VA tempatan dan tamoxifen atas sel 
kanser payu dara, MCF7 dengan usaha untuk mengurangkan kesan bukan selektif atas 
sel normal, NIH 3T3. Aktiviti sitotosisiti dengan VA sahaja dan kombinasi dengan 
tamoxifen atas sel MCF7 dan NIH 3T3 telah dinilaikan dengan MTT asai. Nilai IC50 
untuk MCF7 bagi VA (1.10 ± 1.78 mg/ml), tamoxifen (0.06 ± 0.04 mg/ml) dan 
kombinasi (0.09 ± 0.10 mg/ml) telah diperolehi. VA juga didapati tidak 
membahayakan sel normal dan meningkatkan nilai IC50 untuk NIH 3T3 dalam rawatan 
kombinasi (tamoxifen sahaja: 0.28 ± 0.22 mg/ml, kombinasi: 3.69 ± 2.74 mg/ml). 
Kombinasi antagonistik (CI>1) juga ditemui antara VA dan tamoxifen. Rawatan 
kombinasi mempunyai kesan anti proliferatif atas sel MCF7 dan kurangan toksisiti 
xv	
	
atas sel normal. Pewarnaan nukleus dengan Hoechst 33258 mencadangkan kejadian 
apoptosis berdasarkan kehadiran pendarflour yang terang dalam sel yang dirawat 
dengan rawatan kombinasi. Kesimpulannya, VA menunjukkan potensi pilihan anti 
kanser atas sel MCF7 dengan kemungkinan melalui mendorong apoptotik kematian 
sel dan ia mempunyai peluang yang cerah untuk digunakan secara klinikal pada masa 
hadapan. 
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THE ANTICANCER EFFECT OF LOCAL VERNONIA AMYGDALINA IN 
COMBINATION WITH STANDARD CHEMOTHERAPY DRUG, 
TAMOXIFEN ON BREAST CANCER CELL LINE, MCF-7 
 ABSTRACT 
 
Vernonia amygdalina (VA) is a broadly used local plant in Africa for both nutritional 
and therapeutic purposes. Nevertheless, different geographical origins, locality, 
climate conditions and time of harvesting could influence the biological activities of 
the plant. Albeit of the advancement in medical field, the prevalence of breast cancer 
still increases globally and many data have shown that among all the different types of 
cancers, it is one of the cancers that contribute to the majority of the mortality. 
Moreover, the risk and detrimental side effects of chemotherapy are fast compensating 
its benefits. Therefore, this study focused on combination treatment of local VA and 
tamoxifen towards breast cancer cell line, MCF7 in an effort to reduce the non-
selective effect on normal cells, NIH 3T3. The cytotoxicity activities of VA alone and 
combination with tamoxifen towards MCF7 and NIH 3T3 cell lines were examined 
using MTT assay. The IC50 values on MCF7 for VA (1.10 ± 1.78 mg/ml), tamoxifen 
(0.06 ± 0.04 mg/ml) and combination (0.09 ± 0.10 mg/ml) were obtained. VA was 
also found to be non-deleterious towards normal cells and had the IC50 values of NIH 
3T3 raised in combination treatment (tamoxifen alone: 0.28 ±  0.22 mg/ml, 
combination: 3.69 ±  2.74 mg/ml). Antagonistic combination (CI>1) was also 
discovered between VA and tamoxifen. The combination treatment managed to have 
an anti-proliferative effect on MCF7 cells and reduced toxicity on normal cells. 
xvii	
	
Nuclear staining by Hoechst 33258 suggested the occurrence of apoptosis based on the 
presence of bright fluorescence in the cells treated with combination treatment. In 
conclusion, VA exhibited potential selective anticancer properties in MCF7 cells by 
possibly inducing apoptotic cell death and it has a promising opportunity to be used 
clinically at the future.   
 
     CHAPTER 1  
            INTRODUCTION 
1.1 Background of Study 
Cancer is a main public health burden in both developing and developed countries 
and is the second leading cause of death after cardiovascular disease. Six million out 
of ten million patients died annually. By 2030, the deaths from cancer worldwide are 
estimated to continue surging with a projected 12 million deaths (Alawode, 2013). 
Generally, all cancers are related to the faulty genes that control cell growth and 
death. This unusual growth of cells in body is lethal as they will invade and destroy 
normal cells (Prakash et al., 2013). Inheritance plays a bigger role in deciding the 
risk for a small proportion of cancers such as breast, colorectal and prostate 
compared with others. Familial cancers arise from the interplay between common 
gene variations and lifestyle or environmental risk factors like smoking, dietary 
imbalances, chemicals and radiation. BRCA1 or BRCA2 genes are examples of 
inherited mutations that cause the prevalence of breast and ovarian cancers to be 
much more typical in some families. However, most cancers are not the 
consequences of inherited genes (Howard et al., 2015).  
Radiotherapy is a crucial modality for cancer cure and in the treatments of loco-
regional growths that is impossible to be removed by surgery like those of advanced 
lung, neck and head cancers. It is gauged that around one half of the cancer patients 
are benefitted from it. Vomiting, nausea, diarrhoea and others are some of the 
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common pathological alterations in living system generated by radiation. Besides 
radiotherapy, chemotherapeutic agents used in latest clinical practice have been 
playing a remarkable role in lessening morbidity or mortality and in improving 
patient’s quality of life (Pinto, Moreira and Simons, 2011). However, it has a myriad 
of downsides mainly because of the severe side effects produced as a consequence of 
damage to tissues. It is due to most anticancer drugs that are used in chemotherapy 
have slender therapeutic window, develop multi drug resistance, pose unspecific 
biodistribution upon intravenous administration resulting intolerable side effects to 
healthy tissues especially gastrointestinal tract and bone marrow (Pinto, Moreira and 
Simons, 2011; Tsakalozou, Eckman and Bae, 2012). Consequently, these drawbacks 
of conventional chemotherapeutic strategies often lead to treatment delay or 
discontinuance, suboptimal dosing and decreased patient compliance to therapy. 
Besides that, in a landmark UK study conducted by Wallington et al (2016), they 
discovered that people who receive chemotherapy are killed by the chemotherapy 
treatment and not by the cancer itself within 30 days of starting treatment. 
Furthermore, they also advised physicians to be more cautious in deciding 
chemotherapy to the patients especially to older and more infirm patients whom 
might be better without it.  
A survey conducted by the National Centre for Complementary and Integrative 
Health on Complementary and Alternative Medicine (CAM) use depicted that a lot 
of people make use of CAM to improve their quality of lives. Rockwell, Liu and 
Higgins (2005) also added that its usage has escalated drastically in recent years. A 
survey of patients in clinical trials at NIH disclosed that 63% used at least one form 
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of CAM with an average of two CAM per patient. Furthermore, a study revealed that 
10.6% of women that were being treated for early stage breast cancer had been using 
at least one CAM at the time of diagnosis while an extra 28.1% commenced using 
CAM after surgery (Rockwell, Liu and Higgins, 2005; Howard et al., 2015).  
Vernonia amygdalina (VA) or more commonly known as bitter leaf is an ordinary 
medium sized shrub with numerous bitter principles in every part of the plant. It 
grows throughout the African tropics. It is a broadly used local plant in Nigeria for 
both nutritional and therapeutic purposes. The leaf decoction of the plant is 
traditionally utilised as an anti diabetic remedy apart from its numerous uses in 
ancient times which include treatment of gastrointestinal problems, schistomiasis and 
amoebic dysentery (Akah and Okafor, 1992; Erasto, Grierson and Afolayan, 2006). 
However, different geographical origins, locality, climate conditions and time of 
harvesting could influence the biological activities of the plant. Ngbolua et al (2011) 
explained that this quantitative variations are influenced by growing conditions like 
light intensity, temperature, humidity or other stress factors. In a research carried out 
by Wang et al (2014), they discovered that the chemical compositions of the leaves of 
same species from different countries vary which resulted in the variation in the 
antioxidant activities.  
Therefore, this study focused on combination treatment of VA and tamoxifen towards 
breast cancer cell line in an effort to reduce the non-selective effect on normal cells. 
The analysis of combination index (CI) was conducted in order to confirm whether it 
acts synergistically or antagonistically.   
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1.2 Rationale of Study 
Plants have been an ideal source of medicine since early times. The usage of plants in 
curing numerous human diseases has been recorded in Indian literature and 
Ayurveda. Besides that, medicinal plants have been serving as precious starting 
materials for drug development in both developing and developed countries and there 
has been a great deal of interest nowadays in the role of complementary and 
alternative medicines for the treatment of many acute and chronic diseases. Albeit of 
the advancement in medical field, the prevalence of breast cancer still increases 
globally and many data have shown that among all the different types of cancers, it is 
one of the cancers that contribute to the majority of the mortality. Moreover, the risk 
and detrimental side effects of chemotherapy are fast compensating its benefits. 
Thus, the anti cancer potential possessed by VA to work with the standard 
chemotherapy drug, tamoxifen in order to lessen the non-selective effect of 
chemotherapy is the reason to conduct this research project. 
1.3 Objectives 
1.3.1 General Objective 
The general objective of this study is to determine the anticancer effect of VA and its 
combination with tamoxifen in human breast cancer cell line, MCF 7. 
1.3.2 Specific Objectives 
1) To investigate the cytotoxicity effect of VA towards malignant cell MCF-7. 
2)  To investigate the cytotoxicity effect of VA towards non-malignant cell, NIH 
3T3. 
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3) To compare the effectiveness of cancer treatment between VA alone and in 
combination with tamoxifen. 
4) To evaluate the mechanism of cell death induced by VA by assessing alterations 
in nuclear morphology. 
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     CHAPTER 2 
    LITERATURE REVIEW  
2.1 Cancer 
Cancer is the uncontrolled and abnormal growth of the normal cells. Changes to the 
DNA that pile up over time cause the transformation of a cell and the alteration in the 
genetic information, resulting in the inability of the cell to execute its functions 
properly. A main attribute of cancer cells is their capability to divide rapidly. The 
accumulation of cancer cells is known as a tumour. If the growing tumour does not 
occupy the surrounding tissue, it is denoted as benign (Figure 2.1a) while a 
malignant tumour is the one that spreads to nearby or distant tissues (Figure 2.1b). 
The malignant cells exhibit a myriad of biological features whereby they grow 
rapidly, invade nearby tissues and often metastasise to tissues that are unrelated to 
the primary location. Furthermore, increased abnormality of mitosis, vessel 
infiltration, nuclear atypic, neoangiogenesis, telomerase expression, genetic 
alterations and escape from apoptosis are some other attributes of a malignant cell. In 
contrast, benign neoplasms grow more slowly but may compress nearby normal 
tissues. Figure 2.2 illustrates the cytological and histological changes that happen 
during tumorigenesis (Almeida and Barry, 2010; Tanaka et al., 2013).    
All tumours commence with mutations that amass in the DNA or genetic information 
of a single cell leading it and its offspring to behave abnormally. The mutations may 
affect different genes that control cell growth and division. Some of these genes are 
called tumour suppressor genes which are responsible to repair DNA mistakes, slow  
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Figure 2.1 Benign vs malignant cancers. (a) A benign tumour is a bunch of cells that 
stays within the tissue in which it initially developed. (b) The intrusion of cancer 
cells into nearby tissues is the indication of a malignant tumour. Malignant cells may 
break away from the tumour and move to other sites in the body via the process of 
metastasis (Almeida and Barry, 2010). 
 7
Figure 2.2 Differentiation and atypic of normal, preneoplastic and neoplastic cells. 
Cellular differentiation is reduced during carcinogenesis. Nuclear atypic and 
frequency of mitoses including uncommon mitoses rise during carcinogenesis. The 
abnormal mitosis in this figure is tripolar mitosis (Tanaka et al., 2013). 
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down cell division and induce apoptosis. When these genes do not work properly, 
cells can grow out of control and lead to cancer. Mutations can also prompt certain 
normal genes to turn into oncogenes. Proto-oncogenes are genes that help cells to 
grow but when it mutates or there are too many copies of it, it can be turned on 
indelibly or triggered when it is not supposed to be. Consequently, the cells grow out 
of control which can result in cancer. Furthermore, most cancer-causing mutations 
involving oncogenes are acquired and the oncogenes are generally activated by 
chromosome rearrangements and gene duplications. Nonetheless, as we have two 
copies of most genes and one from each chromosome in a pair, in order for a gene to 
stop functioning completely and potentially give rise to cancer, both copies have to 
be mutated (American Cancer Society, 2015).  
DNA changes can be inherited or sporadic. Inherited mutations are present in the 
DNA conferred by the sperm and/or egg at the moment of fertilization and since all 
the cells in the body came from this first cell, this kind of mutation can be passed on 
to the next generation. This type of mutation is also known as germline or hereditary. 
Sporadic mutations happen spontaneously during the lifespan of a cell due to many 
reasons. It can be a result of a mistake made when a cell duplicates its DNA prior to 
dividing, the wrong repair of a damaged DNA molecule or chemical alteration of the 
DNA where each of which disrupts the expression of the genetic information. It takes 
place in one cell and then is passed on to any new cells. It is also termed as acquired 
mutation since it can be caused by substances that we are exposed to, such as 
radiation, cigarette smoke, diet and hormones. Generally, 90-95% of diagnosed 
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cancers seem to be sporadic in nature and have no heredity basis (Almeida and Barry, 
2010; American Cancer Society, 2015). 
Besides inheritance, environmental factors like lifestyle (nutrition, physical activity, 
tobacco use, excessive alcohol assumption), naturally occurring exposures 
(infectious agents, radon gas, ultraviolet light), medical treatments that comprise of 
radiation and medicines such as hormone drugs, chemotherapy or drugs that suppress 
the immune system as well as other exposures in workplace and household can 
contribute to the cause of cancer. In this case, substances and exposures that lead to 
cancer are termed as carcinogens. Moreover, the risk of developing cancer ultimately 
depends on various factors like the way, length and intensity of the exposure as well 
as the person’s genetic makeup (American Cancer Society, 2015).  
2.1.1 Types of Cancer 
There are more than 100 identified types of cancers where all of them come with 
different symptoms and causes. Normally, the cancers are named based on the part of 
the body in which they emerge. Some tumours are distinguished to reflect the type of 
tissues they originate, with the suffix -oma, meaning tumour. Table 2.1 illustrates 
some of the common tumour terminologies. On top of that, sarcomas, carcinomas, 
lymphomas and leukemias are the major types of cancers. Around 90% of human 
cancers are carcinomas which arise in the epithelium or skin of the internal organs, 
body cavities and glands. Breast, lung, colorectal, skin and prostate are the tissues 
that habitually give rise to carcinomas. Sarcomas are less ordinary than carcinomas 
and incorporate the transformation of cells in connective tissue like bone, cartilage, 
 10
fat or muscle. There are a myriad of sarcoma subtypes and they can grow at any part 
of the body but most commonly in the legs or arms. Besides that, some types of 
cancers do not form solid tumours. For instance, leukemias are cancers of the bone 
marrow which causes overproduction and premature release of immature white blood 
cells. Another example is lymphomas, the cancers of lymphatic system that acts as 
the body’s immune defence that consists of lymph vessels, lymph nodes and lymph 
(Almeida and Barry, 2010).    
Table 2.1 Tumour terminology (Almeida and Barry, 2010). 
Prefix Cell type Benign tumour Malignant 
tumour
Tissue 
affected
Tumours of epithelial 
cells: 
Adeno- Gland Adenoma Adenocarcinom
a
Breast, colon/
rectum, lung, 
ovary, 
pancreas, 
prostate
Basal cell Basal cell Basal cell 
adenoma
Basal cell 
carcinoma
Skin
Squamous cell Squamous 
cell
Keratoacanthom
a
Squamous cell 
carcinoma
Esophagus, 
larynx, lung, 
oral cavity, 
pharynx, skin, 
cervix
Melano- Pigmented 
cell
Mole Melanoma Skin
Tumours of supporting 
tissue origin: 
Hemangio- Blood 
vessels
Hemangioma Hemangiosarco
ma
Blood vessels
Lipo- Fat Lipoma Liposarcoma Fat cells
Meningio- Meninges Meningioma Meningiosarco
ma
Brain
Myo- Muscle Myoma Myosarcoma Muscle
Osteo- Bone Osteoma Osteosarcoma Bone
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2.1.2 Cancer Treatment 
The most usual treatments for cancer are radiation, surgery and chemotherapy. 
Radiation is used to kill or at least slow down the growth of cancer cells. It can be 
used alone or combined with surgery or chemotherapy. Surgery is opted to remove 
some or all of the body parts that are affected but it is not useful for some types of 
cancer like leukaemia which is best treated with drugs (American Cancer Society, 
2015). Chemotherapy is the usage of drugs to hinder their growth or kill cancer cells. 
It is administered either by intravascular or in a pill and since the drugs travel to 
nearly all parts of the body, they are essential for cancer that has spread (American 
Cancer Society, 2015). Since chemotherapies do not target specific genetic 
abnormalities related with tumour cells, the healthy dividing cells are also affected 
almost as critically as the tumour cells, resulting in the vastly debilitating side effects 
observed such as gastrointestinal toxicity, hair loss and myelosuppression. 
Occasionally, poor quality of life and declining effectiveness exacerbated the chances 
of patients to survive, particularly those that are in late stage cancer treatments. Table 
2.2 illustrates some of the common examples of chemotherapeutic agents (Meyers, 
2007). 
Cancers of blood and 
lymphatic origin:
Lympho- Lymphocyte Lymphoma
Lymphocytic 
leukemia
Lymhocytes
Myelo- Bone 
marrow
Myeloma
Myelogenous 
leukemia
Granulocytes
Prefix Cell type Benign tumour Malignant 
tumour
Tissue 
affected
 12
Table 2.2 Examples of conventional cancer chemotherapeutic agents (Meyers, 2007). 
2.2 Epidemiology of Cancer 
2.2.1 Cancer Worldwide 
Cancer is a major cause of morbidity and mortality with around 14 million new cases 
and 8 million cancer related fatality in 2012. It is also estimated that there are 182 
and 102 per 100,000 cases of incidence and mortality respectively. For men, the five 
most common locations of cancer diagnosed in 2012 were lung (16.7%), prostate 
(15.0%), colorectum (10.0%), stomach (8.5%) and liver (7.5%). For women, breast 
(25.2%) is the highest incident sites of cancer followed by colorectum (9.2%), lung 
(8.7%), cervix (7.9%) and stomach (4.8%). In addition, the highest incidence rates 
are related with the high income countries of western Europe and North America 
alongside Japan, South Korea, New Zealand and Australia. World Cancer Report 
2014 reveals that the cancer burden is projected to rise by approximately 70% 
globally in 20 years but the greatest impact will be on the lowest income nations with 
the least developed cancer services. Figure 2.3 and Figure 2.4 below show the 
estimated global annual numbers of of new cases and cancer deaths for the most vital 
types of cancer for men and women (World Health Organization, 2014). 
Drug Category
Methotrexate Antimetabolite
Taxol Spindle modulator
Cyclophosphamide Alkylating agent
Cisplatin Platinum-DNA complexes
Doxorubicin DNA intercalating/topoisomerase inhibitor
 13
Figure 2.3 Estimated world cancer incidence proportions by major sites in men and 
women, 2012 (World Health Organization, 2014). 
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Figure 2.4 Estimated world cancer mortality proportions by major sites in men and 
women, 2012 (World Health Organization, 2014). 
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2.2.2 Cancer in Malaysia 
In Malaysia, National Cancer Institute (2016) reported that cancer contributed 
13.56% of all deaths occurred in the Ministry of Health Hospitals in 2015. It was the 
third most usual cause of death followed by diseases of circulatory system (22.77%) 
and respiratory system (18.54%). A total number of 103,507 newly developed cancer 
cases were diagnosed in Malaysia between 2007 to 2011 of which 56,713 (54.8%) 
were reported in females and 46,794 (45.2%) in males as announced by the 
Malaysian National Cancer Registry. Moreover, as mentioned in the report, the risk 
of females getting cancer was 1 in 9 and for males was 1 in 10. The five most 
common cancers among males were cancers of colorectum (16.3%), lung (15.8%), 
nasopharynx (8.1%), lymphoma (6.8%) and prostate (6.7%). For females, the five 
most common cancer were breast (32.1%), colorectum (10.7%), cervix uteri (7.7%), 
ovary (6.1%) and lung (5.6%). 
2.3 Breast Cancer 
Breast cancer is the most frequently diagnosed cancer and cause of cancer death 
among women in which an estimated 1.7 million new cases (25% of all cancers in 
women) and 0.5 million cancer deaths (15% of all cancer deaths in women) in 2012 
(World Health Organization, 2014). Since 1989, the mortality rates for breast cancer 
have been decreased steadily with the largest drop in younger women from 2006 to 
2010, probably thanks to the improvements in early detection and treatment. Yet, 
breast cancer still remains the highest incidence of all organ sites of cancers in adult 
women in the USA and health discrepancies prevail in that there are huge gaps in 
breast cancer survival by race (Kumar, Abbas and Aster, 2013). The American 
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Cancer Society (2017a) estimated that in 2017, about 252,710 new cases of invasive 
breast cancer will be diagnosed in women. Moreover, around 63,410 new cases of 
carcinoma in situ will be diagnosed and approximately 40,610 women will succumb 
to breast cancer.   
In Malaysia, female breast cancer was accounted for 32.1% of all cancer among 
females. The incidence was highest among Chinese followed by Indian and Malay in 
which the lifetime risk for Chinese was 1 in 22, Indian 1 in 24 and Malay 1 in 35. 
Figure 2.5 and Figure 2.6 below illustrate age-specific incidence rate of female breast 
cancer from 2007-2011 and the stages respectively (National Cancer Institute, 2016). 
2.3.1 Breast Cancer Treatment 
Owing to the availability of mammographic screening, carcinomas often are 
recognised even before they become observable. The mean invasive carcinoma 
detected by mammographic screening is around 1 cm in size and only 15% of these 
have yielded nodal metastases. Besides that, DCIS is also detected prior to the 
development of invasive carcinoma during screening most of the time (Kumar, 
Abbas and Aster, 2013). There are few alternatives to treat breast cancer depending 
on its stage and type. Certain treatments are local, meaning the tumour is treated 
without affecting the rest of the body. Surgery and radiation therapy are two 
examples of local therapy used for breast cancer. Most women with breast cancer 
have some type of surgery as part of their treatment. It may be done to remove as 
much of the cancer as possible (mastectomy or breast-conserving surgery), determine  
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Figure 2.5 Female Breast: age-specific incidence rate, Malaysia, 2007-2011 
(National Cancer Institute, 2016). 
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Figure 2.6 Female Breast Cancer in Malaysia: Stage (National Cancer Institute, 
2016). 
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whether the cancer has spread to the lymph nodes under the arm, breast 
reconstruction reconstruction and relieve symptoms of advanced cancer. Besides that, 
bilateral prophylactic mastectomy is a highly effective approach to prevent the 
development of breast cancer in women with BRCA mutations. This procedure is 
linked with a 90% reduction in the development of breast cancer in these women and 
an even higher (95%) decrease in breast cancer among those who had their ovaries 
removed (World Health Organization, 2014).      
Lumpectomy and mastectomy are two main types of surgery. Lumpectomy or 
sometimes known as quadrantectomy, partial mastectomy or segmental mastectomy 
is a surgery where only the part of the breast containing cancer is removed while 
mastectomy is to remove the whole breast including all of the breast tissue and 
sometimes other nearby tissues (American Cancer Society, 2017b). For radiation 
therapy, it is a treatment with high energy rays or particles that demolish cancer cells. 
Two major types of radiation therapy are external beam radiation and internal 
radiation (brachytherapy). The external radiation comes from a machine outside the 
body while internal radiation requires a radioactive source to be put inside the body 
for a short period. Normally it can be used after mastectomy to lessen the chance of 
cancer reoccurrence or when the cancer has spread to other parts of the body 
(American Cancer Society, 2017b). 
Drugs used to cure breast cancer are considered systemic therapies since they can 
reach cancer cells almost anywhere in the body. They can be administered via mouth 
or directly into the bloodstream. Chemotherapy, hormone therapy and targeted 
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therapy can be used to treat different types of breast cancer. Chemotherapy is 
recommended after surgery as an adjuvant to kill any cancer cells that might have 
spread or left behind but cannot be detected even on imaging tests. It also can be 
used before surgery to shrink the tumour so that it can be removed more easily. Last, 
it is preferred to treat advanced breast cancer where it has spread outside the breast 
and underarm area. Some of the most common drugs used for adjuvant and 
neoadjuvant chemo include anthracyclines (doxorubicin and epirubicin), taxanes 
(paclitaxel and docetaxel), 5-fluorouracil, cyclophosphamide and carboplatin. 
Normally, a combination of two or three of these drugs are used. Platinum agents 
(cisplatin, carboplatin), vinorelbine, capecitabine, gemcitabine, eribulin, taxanes and 
anthracyclines are the drugs for advanced breast cancer (American Cancer Society, 
2017b).   
Some types of breast cancer are influenced by hormones in the blood. ER-positive 
and PR-positive breast cancer cells have receptors that attach to estrogen which 
assists them to grow. Hormone therapy is recommended for women with hormone 
receptor-positive breast cancers. It is often used after surgery to help decrease the 
risk of reoccurrence of cancer. It is also initiated prior to surgery or treat cancer that 
has returned after treatment. Hormone therapy is normally taken for at least 5 years 
(American Cancer Society, 2017b). As the ovaries are the prime source of oestrogen 
in premenopausal women, by suppressing or eliminating their functions, the 
oestrogen levels can be lessened. Ovarian ablation or blocking ovarian function can 
be carried out surgically or via radiation and this is normally irreversible. 
Alternatively, ovarian function can be subdued temporarily by gonadotroprin-
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releasing hormone agonists or also termed as luteinising hormone-releasing hormone 
agonists. This drug acts by interfering the signals from the pituitary gland that trigger 
the ovaries to secrete oestrogen. The examples of ovarian suppression drugs are 
leuprolide and goserelin (National Cancer Institute, 2017).  
Furthermore, aromatase inhibitors like anastrozole, letrozole and exemestane are 
used to halt the activity of aromatase, an enzyme that the body utilises to make 
oestrogen in other tissues and in the ovaries. They are used predominantly in 
postmenopausal women since their ovaries produce a huge amount of aromatase. 
Another mechanism to treat hormone-sensitive breast cancer is impede with the 
estrogen’s ability to activate the growth of breast cancer cells. Tamoxifen and 
toremifene are selective oestrogen receptor modulators that bind to oestrogen 
receptors thereby hindering the binding of oestrogen. Besides blocking oestrogen 
activity by binding to estrogen receptors, they can also mimic the effects of oestrogen 
by serving as oestrogen agonists or antagonists depending on the types of tissues 
(National Cancer Institute, 2017).   
Targeted therapy is another type of treatment for breast cancer. In this treatment, the 
targeted drugs will restrict the growth and spread of cancer cells. The cancer cells of 
about 1 in 5 women with breast cancer have excessive HER2/neu on their surfaces. 
These cancers tend to grow and spread more aggressively. A number of drugs 
including trastuzumab, pertuzumab, ado-trastuzumab emtansine, lapatinib and 
neratinib have been designed that target this protein (American Cancer Society, 
2017b). 
 22
The side effects of hormone treatment depend mostly on the type of treatment or the 
specific drug. The most typical side effects are symptoms of menopause such as 
night sweats and hot flashes. In addition, tamoxifen can result in vaginal discharge 
and dryness. Pre-menopausal women that take tamoxifen occasionally will 
experience menstrual changes in which the menstrual periods can become irregular 
or even come to a halt. Furthermore, since tamoxifen behaves like oestrogen in the 
uterus, the risk of uterine sarcoma and endometrial cancer can be surged. Raloxifene 
can increase the risk of blood clots especially in the legs and lungs and stroke in 
some subgroups. Ovarian suppression can lead to bone loss, loss of libido, mood 
swings and depression while aromatase inhibitors raise the risk of angina, heart 
attack, hypercholesterolemia and heart failure, besides causing bone loss, joint pain, 
depression and mood swings. In addition, fulvestrant can result in gastrointestinal 
symptoms, loss of strength and pain (American Cancer Society, 2016; National 
Cancer Institute, 2017). On top of that, many drugs like fluorouracil-epirubicin-
cyclophosphamide, FEC-tamoxifen and cisplatin-methotrexate fluorouracil have 
been used in combination with the aim of increasing efficacy and reducing side 
effects but patients still experience phlebitis, fatigue, nausea, alopecia, anaemia, 
mucositis and myelosuppression together with the well-known long term side effects. 
Table 2.3 depicts the conventional or approved drugs used in breast cancer 
chemotherapy alongside their main mechanisms of action and side effects that are 
most commonly seen (Liao, Apaya and Shyur, 2013). 
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Table 2.3 Summary of major mechanisms of action and common side effects of 
chemotherapeutic drugs approved for breast cancers 
2.4 Tamoxifen 
2.4.1 Chemistry and Pharmacology  
Tamoxifen marketed under the name of Nolvadex, emerged from a research 
programme targeted at developing an antioestrogen oral contraceptive about 50 years 
ago. Nowadays, interest in the use of tamoxifen as oral contraceptives has mainly 
been substituted with interest in the use for prevention and treatment of breast cancer. 
Tamoxifen has intricate pharmacological characteristics and can act as either a pure 
oestrogen agonist, an antagonist or a partial agonist depending on the target organ 
and species examined and the endpoint assessed. It has been discovered that it was 
oestrogenic in the mouse and partial oestrogen agonist in the uterus of the rat. Further 
Chemotherapeutic agent Mechanism of action Side effect
Cyclophosphamide Apoptotic cell death Pulmonary toxicities, weight 
gain
Cisplatin DNA damage, apoptosis Nephrotoxicity
Doxorubicin DNA damage Impaired cognitive function, 
anaemia 
Docetaxel Mitotic inhibition Pulmonary toxicities, colitis, 
diarrhoea
Epirubicin DNA damage Nausea, cardiotoxicity
Fluorouracil Thymidylate synthesise 
inhibition; DNA synthesis 
inhibition
Cardiotoxicity, anemia, GI 
tract toxicity
Gemcitabine Nucleic acid synthesis 
inhibition
GI tract toxicity
Methotrexate Cell cycle arrest Anemia, weight gain, 
jaundice, diarrhoea, loss of 
bone density
Mitomycin DNA alkylating agent Myelotoxicity, fatigue, 
systemic toxicity
Mitoxantrone Topoisomerase inhibition Alopecia, systemic toxicity
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